← All companies

ANRO

Alto Neuroscience, Inc.

ANRO NYSE Pharmaceutical Preparations EDGAR ↗

$27.27

-1.36 -4.75%

Key statistics

from XBRL data in SEC filings

Market cap

$957M

Revenue (TTM)

—

Net income (TTM)

-$74.3M

EPS (TTM)

$-2.43

P/E ratio

—

Dividend yield

—

Free cash flow

-$51.8M

Cash

$264M

Total assets

$276M

Gross margin

—

52-week range

$3.00 – $28.85

Recent SEC filings

40 most recent

Annual, quarterly & current reports

8-K Entered a material agreement Jul 14, 2026 8-K Results of operations (earnings release); Other events Jul 13, 2026 8-K Director or officer change May 28, 2026 8-K Director or officer change; Shareholder vote results May 13, 2026 10-Q Quarter ended 2026-03-31 May 13, 2026 8-K Results of operations (earnings release) May 13, 2026 8-K Other events Apr 1, 2026 8-K Entered a material agreement; Unregistered sale of equity; Other events Mar 16, 2026 10-K Fiscal year ended 2025-12-31 Mar 16, 2026 8-K Results of operations (earnings release) Mar 16, 2026 10-Q Quarter ended 2025-09-30 Nov 12, 2025 8-K Results of operations (earnings release) Nov 12, 2025 8-K Entered a material agreement; Terminated a material agreement; Unregistered sale of equity; Other events Oct 20, 2025 10-Q Quarter ended 2025-06-30 Aug 13, 2025 8-K Results of operations (earnings release); Director or officer change Aug 13, 2025 8-K Director or officer change Jul 8, 2025 8-K Other events Jun 26, 2025 8-K Entered a material agreement; Unregistered sale of equity; Other events Jun 3, 2025 10-Q Quarter ended 2025-03-31 May 14, 2025 8-K Results of operations (earnings release); Shareholder vote results May 14, 2025 10-K Fiscal year ended 2024-12-31 Mar 20, 2025 8-K Results of operations (earnings release); Director or officer change Mar 20, 2025 8-K Other events Feb 12, 2025 8-K Entered a material agreement; Results of operations (earnings release) Feb 3, 2025 8-K Entered a material agreement; Took on a direct financial obligation; Unregistered sale of equity Jan 16, 2025 10-Q Quarter ended 2024-09-30 Nov 12, 2024 8-K Results of operations (earnings release) Nov 12, 2024 8-K Other events Oct 22, 2024 10-Q Quarter ended 2024-06-30 Aug 13, 2024 8-K Results of operations (earnings release) Aug 13, 2024 8-K Entered a material agreement; Took on a direct financial obligation; Unregistered sale of equity Jul 29, 2024 8-K Director or officer change May 21, 2024 10-Q Quarter ended 2024-03-31 May 14, 2024 8-K Results of operations (earnings release) May 14, 2024 10-K Fiscal year ended 2023-12-31 Mar 21, 2024 8-K Results of operations (earnings release) Mar 21, 2024 8-K Director or officer change Mar 11, 2024 8-K Amended charter or bylaws Feb 6, 2024

Other filings

SCHEDULE 13G Jul 27, 2026 SCHEDULE 13G Jul 20, 2026